Catalyst heads back to the FDA in search of an elusive OK after Firdapse scores high in new PhIII
About 18 months after the FDA thumbed Catalyst Pharmaceuticals $CPRX back to the clinic with a demand for more clinical data on its lead drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
